Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

GARBER, Alan; KING, Allen; DEL PRATO, Stefano; SREENAN, Seamus; BALCI, MUSTAFA; MUNOZ-TORRES, Manuel; ROSENSTOCK, Julio; ENDAHL, Lars; FRANCISCO, Ann; HOLLANDER, Priscilla

doi:10.1016/s0140-6736(12)60205-0

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

GARBER A. J., KING A. B., DEL PRATO S., SREENAN S., BALCI M. K., MUNOZ-TORRES M., ...Daha Fazla

LANCET, cilt.379, sa.9825, ss.1498-1507, 2012 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 379 Sayı: 9825
Basım Tarihi: 2012
Doi Numarası: 10.1016/s0140-6736(12)60205-0
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1498-1507
Akdeniz Üniversitesi Adresli: Evet

Özet

Background Basal insulin therapy does not stop loss of beta-cell function, which is the hallmark of type 2 diabetes mellitus, and thus diabetes control inevitably deteriorates. Insulin degludec is a new, ultra-longacting basal insulin. We aimed to assess efficacy and safety of insulin degludec compared with insulin glargine in patients with type 2 diabetes mellitus.